Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

Cytokine-Induced Killer Cells

Phase 3Biologic

TThe First People's Hospital of Changzhou

Cytokine-Induced Killer Cells is one of 340 biologic programs targeting Esophageal Cancer. It is currently in Phase 3.

11

Indications

19

Total Trials

11

Active Trials

339

Competitors

Pipeline

Status by Indication[3][1]

Indication

Esophageal CancerNot yet recruiting

LymphomaNot yet recruiting

Ovarian CarcinomaActive, not recruiting

Lung AdenocarcinomaActive, not recruiting

MelanomaNot yet recruiting

Bladder CancerActive, not recruiting

Gastric CancerActive, not recruiting

Cervical CancerActive, not recruiting

Colorectal CancerCompleted

CholangiocarcinomaActive, not recruiting

Esophageal CancerPhase 2

Not yet recruiting

LymphomaPhase 2

Not yet recruiting

Ovarian CarcinomaPhase 2

Active, not recruiting

Lung AdenocarcinomaPhase 2

Active, not recruiting

MelanomaPhase 2

Not yet recruiting

Bladder CancerPhase 2

Active, not recruiting

Gastric CancerPhase 2

Active, not recruiting

Cervical CancerPhase 2

Active, not recruiting

Colorectal CancerPhase 3

Completed

CholangiocarcinomaPhase 3

Active, not recruiting

Showing 10 of 11 indications

Competition

Competitive Landscape

401 competitors in Lymphoma

#DrugCompanyPhaseTrials

Cytokine-Induced Killer Cells

TThe First People's Hospital of Changzhou

Zofran

Cabenuva

Norvir

Emend

CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Kenalog

BBausch Health Americas, Inc.

Nuvigil

NNuvo Research GmbH

Elitek

AAzienda U.S.L. 1 di Massa e Carrara

Decadron

QQuince Therapeutics S.p.A.

Solu-Medrol

MMassachusetts Eye and Ear Infirmary

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2030

Phase 2Active, not recruiting

Bladder Cancer

NCT02489890

Q2 2033

Phase 2Active, not recruiting

Gastric Cancer

NCT02485015

Q3 2033

Phase 2Active, not recruiting

Lung Adenocarcinoma

NCT02493582

Phase 2/3Active, not recruiting

Cholangiocarcinoma

NCT02482454

Q2 2040

Phase 2Active, not recruiting

Ovarian Carcinoma

NCT02487693

Phase 2Active, not recruiting

Cervical Cancer

NCT02490748

Clinical

Trials by Indication[1]

Colorectal Cancer2 trials

Radiofrquency Ablation Combined With Cytokine-induced Killer Cells for Colorectal Cancer Liver Metastases

Completed·TThe First People's Hospital of Changzhou·Phase 2/3·NCT02419677·60 enrolled

The Study of CIK Plus S-1 and Bevacizumab as Maintenance Treatment for Patients With Advanced Colorectal Cancer

Active, not recruiting·TThe First People's Hospital of Changzhou·Phase 2·NCT02487992·1,200 enrolled

Cytokine-Induced Killer Cells2 trials

Treatment of Metastatic Tumors of the Urogenital Area With Cytokine-induced Killer Cells

Unknown status·IInstitute of Biophysics and Cell Engineering of National Academy of Sciences of Belarus·Phase 1/2·NCT05108077·20 enrolled

Efficacy of Adjuvant Cytokine-induced Killer Cells in Colon Cancer

Unknown status·YYanjuan Zhu·Phase 2·NCT01929499·210 enrolled

Pancreatic Cancer1 trial

Autologous Cytokine-induced Killer Cells Combined Chemotherapy in Advanced Pancreatic Cancer

Terminated·HHenan Cancer Hospital·Phase 2·NCT03002831·13 enrolled

Gastric Cancer1 trial

The Study of Apatinib Plus CIK as the Third Line Therapy for Patients With Advanced Gastric Cancer

Active, not recruiting·TThe First People's Hospital of Changzhou·Phase 2·NCT02485015·80 enrolled

Allogeneic Hematopoietic Cell Transplant1 trial

Cytokine Induced Killer Cells as Post-Transplant Immunotherapy Following Allogeneic Hematopoietic Cell Transplantation

Unknown status·RRobert Negrin·Phase 1·NCT00185757·20 enrolled

12 more indications

Advanced Solid Tumor1 trial

Study of DC-CTL Combined With CIK for Advanced Solid Tumor

Unknown status·UUnknown Sponsor·Phase 1/2·NCT03047525·200 enrolled

Immunotherapy1 trial

The Adoptive Immunotherapy for Solid Tumors Using Modified Autologous CIK Cells

Enrolling by invitation·SSiriraj Hospital·Phase 1/2·NCT01868490·20 enrolled

Lymphoma1 trial

Treatment of CIK for Patients With Refractory Non-Hodgkin Lymphoma

Not yet recruiting·TThe First People's Hospital of Changzhou·Phase 2·NCT02497898·1,000 enrolled

Esophageal Cancer1 trial

CIK in Treating Patients With Esophageal Cancer

Not yet recruiting·TThe First People's Hospital of Changzhou·Phase 2·NCT02490735·2,000 enrolled

Bladder Cancer1 trial

CIK in Treating Patients With Bladder Cancer

Active, not recruiting·TThe First People's Hospital of Changzhou·Phase 2·NCT02489890·1,500 enrolled

Lung Adenocarcinoma1 trial

The Study of Apatinib Plus CIK as the Third Line Therapy for Advanced Lung Adenocarcinoma Patients With Wild-Type EGFR

Active, not recruiting·TThe First People's Hospital of Changzhou·Phase 2·NCT02493582·400 enrolled

Melanoma1 trial

Cytokine-induced Killer Study for Patients With Stage II Melanoma

Not yet recruiting·TThe First People's Hospital of Changzhou·Phase 2·NCT02498756·300 enrolled

Cholangiocarcinoma1 trial

Radiofrquency Ablation Combined With Cytokine-induced Killer Cells for the Patients With Cholangiocarcinoma

Active, not recruiting·TThe First People's Hospital of Changzhou·Phase 2/3·NCT02482454·50 enrolled

Ovarian Carcinoma1 trial

Radiofrquency Ablation Combined With Cytokine-induced Killer Cells for the Patients With Ovarian Carcinoma

Active, not recruiting·TThe First People's Hospital of Changzhou·Phase 2·NCT02487693·50 enrolled

Treatment1 trial

CIK Treatment for HCC Patient Underwent Radical Resection

Completed·SSun Yat-sen University·Phase 3·NCT01749865·200 enrolled

Cervical Cancer1 trial

Radiofrquency Ablation Combined With Cytokine-induced Killer Cells for the Patients With Cervical Cancer

Active, not recruiting·TThe First People's Hospital of Changzhou·Phase 2·NCT02490748·10 enrolled

Myelodysplastic Syndrome1 trial

Cytokine-induced Memory-like NK Cells in Patients With Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)

Terminated·WWashington University School of Medicine·Phase 1/2·NCT01898793·89 enrolled

Sources

References

[1]
ClinicalTrials.gov — 19 trial records for Cytokine-Induced Killer Cells. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Cytokine-Induced Killer Cells compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Cytokine-Induced Killer Cells. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — The First People's Hospital of Changzhou company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Phase 3[1]
Company: TThe First People's Hospital of Changzhou

Related News